Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maribeth Tillmann"'
Publikováno v:
Journal of Biological Chemistry. 274:1172-1179
Incubation of HTC rat hepatoma cells with the cyclic nucleotide analogue 8-bromo-cAMP results in a 3-fold increase in the rate of degradation of type-1 plasminogen activator-inhibitor (PAI-1) mRNA. Previous studies utilizing HTC cells stably transfec
Publikováno v:
Journal of Biological Chemistry. 273:14261-14268
Type-1 plasminogen activator-inhibitor (PAI-1) is a major physiologic inhibitor of plasminogen activation. Incubation of HTC rat hepatoma cells with the cyclic nucleotide analogue, 8-bromo-cAMP, causes a dramatic increase in tissue-type plasminogen a
Publikováno v:
Journal of Virology. 68:4597-4608
The human T-cell lymphotropic virus type I (HTLV-I)-encoded protein, Tax, is capable of trans-activating HTLV-I transcription by interacting with specific sequences in the HTLV-I long terminal repeat (LTR) which comprise an inducible enhancer contain
Autor:
Maribeth Tillmann, Brian Wigdahl
Publikováno v:
Seminars in Neuroscience. 3:131-139
In general, the acquired immunodeficiency syndrome (AIDS) is considered to be a disease of the immune system; however, other organ systems, including the nervous system, are targets of the human immunodeficiency virus (HIV). It is now well establishe
Publikováno v:
Journal of neurovirology. 1(1)
Human T cell lymphotropic virus type I (HTLV-I) encodes the trans-activator, Tax, which facilitates viral transcription from three 21 bp repeated elements within the U3 region of the long terminal repeat (LTR). Electrophoretic mobility shift (EMS) an
Autor:
Renee Wessner, Maribeth Tillmann, Brian Wigdahl, Fred C. Krebs, Maureen M. Goodenow, Steven M. Pomeroy
Publikováno v:
Advances in neuroimmunology. 4(3)
Retroviruses have been implicated as causative agents of a variety of human diseases including malignancy, immune system dysfunction, and neurologic disorders. Despite the isolation of various retroviral agents from patients suffering from malignant
Publikováno v:
Fibrinolysis and Proteolysis. 11:3